期刊
ACS INFECTIOUS DISEASES
卷 3, 期 1, 页码 54-61出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.6b00123
关键词
Staphylococcus aureus; FabI; benzimidazole inhibitor; enoyl-ACP reductase; mode of action
资金
- National Institutes of Health [AI077949, AI110090]
The enoyl-ACP reductase (FabI) enzyme is a well validated target for anti-staphylococcal drug discovery and development. With the goal of finding alternate therapeutics for drug-resistant strains of Staphylococcus aureus, such as methicillin-resistant S. aureus (MRSA), our previously published series of benzimidazole-based inhibitors of the Fabl enzyme from Francisella tularensis (FtFabI) have been evaluated against Fabl from S. aureus (SaFabl). We report here the preliminary structure activity relationship of this series and the prioritization of compounds toward lead optimization. Mutational studies have identified key residues that contribute toward stabilizing the inhibitors in the active site of Fabl. Mutations that do not significantly impact enzyme function but destabilize inhibitor binding are more likely to occur in nature as organisms evolve to evade the action of antibiotics leading to resistance. Identifying these residues provides guidance for minimizing susceptibility to resistance. Additionally, we have identified compounds that elicit antibacterial activity through off-target effects arid observe that close analogs can display differing modes of action (on-target vs off-target) and need to be individually evaluated early on to prioritize compounds for lead optimization. Overall, our data suggest that the benzimidazole scaffold is a promising scaffold for anti-staphylococcal drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据